ACVR2B, Polyclonal Antibody

Activin receptor type-2B; Activin receptor type IIB; ACTR-IIB; ACVR2B

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit Ig

Rabbit

This ACVR2B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected between aa 1 and 30 of human ACVR2B.

Purified Rabbit Polyclonal Antibody (Pab)

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Vial Concentration: 2 (lot specific)

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-ACVR2B antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. ACVR2B (activin A type IIB receptor) displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.

Signal Transduction

Western Blot (WB), ELISA (EIA), Immunohistochemistry (IHC)

WB~~1:1000

Western blot analysis of lysate from human pancreas tissue lysate, using ACVR2B Antibody (S14). MBS9209648 was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 35ug.

Western blot analysis of ACVR2B (N-term) in Jurkat cell line lysates (35ug/lane).ACVR2B (arrow) was detected using the purified Pab.

Western blot analysis of anti-ACVR2B Antibody (N-term) in mouse heart, kidney and brain lysates (35ug/lane). ACVR2B (arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

57724

activin A receptor, type IIB

activin receptor type-2B

Activin receptor type-2B

ACTR-IIB  [Similar Products]

AVR2B_HUMAN

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008]

ACVR2B: a tyrosine-kinase like receptor kinase of the STKR family. The holoreceptor receptor is a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. Each is composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic kinase domain. Type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptor kinases are apparently constitutively active. The IIB receptor displays a 3- to 4-fold higher affinity for activin A than the II receptor.

Protein type: Protein kinase, TKL; Protein kinase, Ser/Thr (receptor); Membrane protein, integral; EC 2.7.11.30; Kinase, protein; TKL group; STKR family; Type2 subfamily

Chromosomal Location of Human Ortholog: 3p22

Cellular Component: integral to plasma membrane; cytoplasm; plasma membrane; receptor complex

Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; metal ion binding; growth factor binding; protein serine/threonine/tyrosine kinase activity; activin binding; activin receptor activity, type II; ATP binding; receptor signaling protein serine/threonine kinase activity

Biological Process: heart development; activin receptor signaling pathway; palate development; signal transduction; protein amino acid phosphorylation; post-embryonic development; BMP signaling pathway; anterior/posterior pattern formation; positive regulation of activin receptor signaling pathway; regulation of transcription, DNA-dependent; transmembrane receptor protein serine/threonine kinase signaling pathway; embryonic foregut morphogenesis; lymphangiogenesis; pancreas development; response to glucose stimulus; mesoderm development; kidney development; gastrulation with mouth forming second; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; positive regulation of osteoblast differentiation; organ growth; skeletal morphogenesis; insulin secretion; activation of protein kinase activity; blood vessel remodeling; determination of left/right symmetry; lung development

Disease: Heterotaxy, Visceral, 4, Autosomal

Harrison, C.A., et al., J. Biol. Chem. 279(27):28036-28044 (2004). Martins da Silva, S.J., et al., Dev. Biol. 266(2):334-345 (2004). Casagrandi, D., et al., Mol. Hum. Reprod. 9(4):199-203 (2003). Shin, B.K., et al., J. Biol. Chem. 278(9):7607-7616 (2003). Schneider-Kolsky, M.E., et al., Placenta 23(4):294-302 (2002).

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.